What Is Pathogen Access and Benefit Sharing?
The WHO Pandemic Agreement’s planned PABS system is intended to pair rapid sharing of pandemic-potential materials and information with more equitable access to resulting health products.
Timeline
- May 20, 2025: The World Health Assembly adopted the WHO Pandemic Agreement.
- After adoption: Member states began negotiating the PABS annex required before the agreement can open for signature.
Pathogen Access and Benefit Sharing, commonly shortened to PABS, is a planned system under the WHO Pandemic Agreement. Its purpose is to connect rapid access to biological materials and sequence information for pathogens with pandemic potential to the timely, fair sharing of vaccines, diagnostics, treatments and other benefits developed from that access. [1][2]
The World Health Assembly adopted the Pandemic Agreement on May 20, 2025, but did not complete every operating rule for PABS. Article 12 says the definitions, modalities, legal nature, terms and conditions are to be developed in an annex. That annex is therefore part of implementation, not a minor optional add-on. [1][2]
The agreement describes access and benefit sharing as linked parts of one mechanism. Participating manufacturers are expected to make a target of 20 percent of their real-time production of relevant vaccines, therapeutics and diagnostics available to WHO, with portions provided as donations and at affordable prices, for allocation according to public-health need. [1][2]
PABS is meant to address a problem exposed during COVID-19: scientific information can move quickly while finished products remain scarce or unevenly distributed. Faster pathogen sharing can support surveillance and product development, while negotiated benefits are intended to give countries a clearer reason and a fairer framework for participating. [1]
The system is not the same as giving WHO authority over national health policy. The agreement states that WHO cannot direct domestic laws or impose measures such as vaccination mandates or lockdowns. Countries negotiate and implement the framework through their own legal processes and retain sovereignty over public-health decisions. [1]
Adoption also did not make the treaty immediately binding everywhere. WHO explains that the agreement will open for signature only after the PABS annex is adopted. It can enter into force after 60 ratifications, and obligations then apply to the countries that become parties under the treaty’s terms. [1][2]
Because negotiations determine the final mechanics, descriptions of PABS should separate agreed objectives from unfinished details. The established direction is rapid pathogen access paired with benefit sharing; the precise contracts, participating entities, governance and operational procedures depend on the annex and later implementation decisions. [1][2]